Novel 2,4-diaminothiazole derivatives
CA 2455753 A1 · Owner: Bowler, Andrew Neil · Inventors: Bowler, Andrew Neil; Hansen, Bo Falck
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel 2,4-diaminothiazole derivatives of the general formula (I) which inhibit GSK-3 (glycogen synthase kinase-3), use of these compounds as medicaments pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful for the treatment of disorders, syndromes diseases and conditions, wherein an inhibition of GSK-3 (glycogen synthase kinase-3) is beneficial especially IGT (impaired glucose tolerance) type 1 diabetes, type 2 diabetes, obesity Alzheimer's disease and bipolar disorder.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 22, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 22, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 22, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.